{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:18:45Z","timestamp":1772849925429,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Malignant cells in chronic lymphocytic leukemia (CLL) show resistance to apoptosis, as well as to chemotherapy, which are related to deletions or mutations of TP53, high expression of MCL1 and BCL2 genes and other abnormalities. Thus, the main goal of the present study was to assess the impact of chlorambucil (CLB) combined with valproic acid (VPA), a known antiepileptic drug and histone deacetylation inhibitor, on apoptosis of the cells isolated from 17 patients with CLL. After incubation with CLB (17.5 \u00b5M) and VPA (0.5 mM), percentage of apoptosis, as well as expression of two TP53 target genes (p21 and HDM2) and two genes from Bcl-2 family (BCL2 and MCL1), were tested. As a result, an increased percentage of apoptosis was observed for CLL cells treated with CLB and VPA, and with CLB alone. Under the treatment with the drug combination, the expression of p21 gene was visibly higher than under the treatment with CLB alone. At the same time, the cultures under CLB treatment showed visibly higher expression of BCL2 than the cultures with VPA alone. Thus, the present study strongly suggests further investigations on the CLB and VPA combination in CLL treatment.<\/jats:p>","DOI":"10.3390\/cells10051088","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T08:05:21Z","timestamp":1619942721000},"page":"1088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of p21, HDM2, BCL2 and MCL1 Genes in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"10","author":[{"given":"Katarzyna","family":"Lipska","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-5887","authenticated-orcid":false,"given":"Agata","family":"Filip","sequence":"additional","affiliation":[{"name":"Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-5272","authenticated-orcid":false,"given":"Anna","family":"Gumieniczek","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Medical University of Lublin, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of Chronic Lymphocytic Leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.14719","article-title":"Chronic Lymphocytic Leukaemia Genomics and the Precision Medicine Era","volume":"178","author":"Ghamlouch","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-013-0268-z","article-title":"Guilty Bystanders: Nurse-Like Cells as a Model of Microenvironmental Support for Leukemic Lymphocytes","volume":"15","author":"Filip","year":"2015","journal-title":"Clin. Exp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic Lyphocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A Review of Programmed Cell Death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell Death: A Review of a Major Forms of Apoptosis, Necrosis and Autophagy","volume":"43","year":"2019","journal-title":"Cell Biol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","article-title":"Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic Proteins","volume":"14","author":"Bokelmann","year":"2008","journal-title":"Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jclinpath-2018-205622","article-title":"Relevance of TP53 for CLL Diagnostics","volume":"72","author":"Catherwood","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Blanco, G., and Espinet, B. (2014). Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We are and Where We Go. BioMed Res. Int., 435983.","DOI":"10.1155\/2014\/435983"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The Role of P53 in Cancer Drug Resistance and Targeted Chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How Does P53 Induce Apoptosis and How Does this Relate to P53-Mediated Tumour Suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620719891356","article-title":"Emerging Treatment Options for Patients with P53-Pathway-Deficient CLL","volume":"10","author":"Aitken","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shamloo, B., and Usluer, S. (2019). P21 in Cancer Research. Cancers, 11.","DOI":"10.3390\/cancers11081178"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-P53 Interaction for Cancer Therapy: Are We There Yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2014.963077","article-title":"Past, Present and Future Role of Chlorambucil in the Treatment of Chronic Lymphocytic Leukemia","volume":"56","author":"Goede","year":"2015","journal-title":"Leuk. Lymphoma."},{"key":"ref_17","first-page":"24","article-title":"Induction of Apoptosis in B-CLL Cells by Selected Histone Deacetylase Inhibitors","volume":"36","author":"Kolano","year":"2011","journal-title":"Cent. Eur. J. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","article-title":"Rituximab Plus Chlorambucil as First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study","volume":"32","author":"Hillmen","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil Plus Rituximab with or without Maintenance Rituximab as First-Line Treatment for Elderly Chronic Lymphocytic Leukemia Patients","volume":"89","author":"Foa","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_20","first-page":"352","article-title":"Chlorambucil Plus Rituximab as Front-Line Therapy in Elderly\/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience","volume":"102","author":"Laurenti","year":"2013","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1874467211666181010161836","article-title":"Combination Treatment of P53-Null HL-60 Cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression","volume":"12","author":"Kwa","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3892\/ol.2013.1565","article-title":"Inhibitory Effect of Valproic Acid on Bladder Cancer in Combination with Chemotherapeutic Agents in Vitro and in Vivo","volume":"6","author":"Wang","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2478\/acph-2020-0021","article-title":"Anticonvulsant Valproic Acid and Other Short-Chain Fatty Acids as Novel Anticancer Therapeutics: Possibilities and Challenges","volume":"70","author":"Lipska","year":"2020","journal-title":"Acta Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.17219\/acem\/29264","article-title":"Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells","volume":"24","author":"Karp","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/leu.2009.176","article-title":"Antileukemic Activity of Valproic Acid in Chronic Lymphocytic Leukemia B Cells Defined by Microarray Analysis","volume":"23","author":"Stamatopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.exphem.2007.06.014","article-title":"Valproic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Through Activation of the Death Receptor Pathway and Potentiates TRAIL Response","volume":"35","author":"Lagneaux","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10495-013-0906-7","article-title":"Valproic Acid Enhances Fludarabine-Induced Apoptosis Mediated by ROS and Involving Decreased AKT and ATM Activation in B-cell-Lymphoid Neoplastic Cells","volume":"19","author":"Yoon","year":"2014","journal-title":"Apoptosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_30","unstructured":"(2021, April 20). Available online: https:\/\/p53.iarc.fr\/TP53GeneVariations.aspx."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1038\/sj.onc.1207004","article-title":"Role of the TRAIL\/APO2-L Death Receptors in Chlorambucil- and Fludarabine-Induced Apoptosis in Chronic Lymphocytic Leukemia","volume":"22","author":"Johnston","year":"2003","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic Acid (VPA) in Patients with Refractory Advanced Cancer: A Dose Escalating Phase I Clinical Trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/10428194.2016.1211276","article-title":"TP53 Gene p72R Polymorphism in Chronic Lymphocytic Leukemia: Incidence and Clinical Significance Amongst Cases with Unmutated Immunoglobulin Receptors","volume":"58","author":"Gemenetzi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jb\/mvu059","article-title":"The Adapter Protein CD2AP Binds to p53 Protein in the Cytoplasm and Can Discriminate its Polymorphic Variants P72R","volume":"157","author":"Panni","year":"2015","journal-title":"J. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Monica, M., Sto\u017cek-Tutro, A., W\u0142adysiuk, H., and Hus, I. (2018). Treatment Options in Chronic Lymphocytic Leukemia (CLL)\u2014A Polish Perspective. J. Health Policy Outcomes Res.","DOI":"10.7365\/JHPOR.2018.1.3"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.15604","article-title":"Outcome of Patients Aged 80 Years or Older Treated for Chronic Lymphocytic Leukaemia","volume":"183","author":"Bahlo","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_37","first-page":"2","article-title":"From Biology to Therapy: The CLL Success Story","volume":"3","author":"Yosifov","year":"2019","journal-title":"HemaShere"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:41Z","timestamp":1760162201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cells10051088"],"URL":"https:\/\/doi.org\/10.3390\/cells10051088","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,2]]}}}